Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United St We ...

Faced with the earlier setbacks with Nuplazid, the company has worked to add to its pipeline, and is hoping for FDA approval of its trofinetide candidate for neurological disorder Rett syndrome in ...

At the time of writing, one therapy has been approved for Rett syndrome, Acadia Pharmaceuticals’ $375,000-per-year Daybue (trofinetide), but Neurogene’s approach could offer a one-shot ...

Diabetes and obesity are two metabolic diseases characterized by insulin resistance and a low-grade inflammation. Seeking an inflammatory factor causative of the onset of insulin resistance ...

After hours: January 28 at 6:27:09 PM EST Loading Chart for ACAD ...

Pre-Market: 5:32:16 a.m. EST ...

Biopharmaceutical company developing drugs for neurological disorders.